4.4 Article

Chronic migraine: Classification and comparisons

期刊

CEPHALALGIA
卷 31, 期 5, 页码 520-529

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102410383590

关键词

Chronic migraine; definition; classification; epidemiology

资金

  1. German Federal Ministry for Education and Research
  2. Allergan, Inc.
  3. Irvine, CA, USA
  4. Allergan
  5. Bayer
  6. German Research Council (DFG)
  7. German Ministry of Education and Research (BMBF)
  8. European Union
  9. Almirall
  10. AstraZeneca
  11. GlaxoSmithKline
  12. Janssen-Cilag
  13. Pfizer

向作者/读者索取更多资源

Objective: The objective of our study was to field test different chronic migraine (CM) criteria and compare CM epidemiological profiles, which include demographic, personal, and lifestyle characteristics, with high-frequency episodic migraine (HFEM) and low-frequency episodic migraine (LFEM). Methods: Questionnaires were mailed to a random sample of 18,000 18-65-year-olds in demographically diverse regions of Germany. The epidemiological data for the three classifications of CM, LFEM and HFEM were assessed using descriptive statistics, Pearson Chi-square, and analysis of variance tests. Results: Among 9350 respondents, CM_I was the most restrictive (N=37, 0.4%), followed by CM_II (N=45, 0.5%) and CM_III (N=185, 2.0%). CM groups did not differ in distribution by age, gender, body mass index, education or smoking and alcohol consumption. Compared to those with LFEM and HFEM, those with CM (CM_III) had significantly different epidemiological profiles. Conclusions: CM prevalence varies by case definition. The epidemiological profiles of the three CM groups are similar but differ significantly from those of HFEM and LFEM. Optimal definitions for clinical practice and epidemiological research require additional field testing.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据